trial · primary record
Metarrestin
Advanced Solid Tumors
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 116 |
| Primary completion | 2028-12-31 |
| Primary endpoint | To identify the maximum tolerated dose (MTD) of metarrestin in subjects with metastatic solid tumors |
| Registry ID | NCT04222413 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:40.532Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04222413
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.